SK285459B6 - Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu medicinálnych produktov, ktoré sú použiteľné na liečenie alebo prevenciu závažných depresívnych porúch - Google Patents

Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu medicinálnych produktov, ktoré sú použiteľné na liečenie alebo prevenciu závažných depresívnych porúch Download PDF

Info

Publication number
SK285459B6
SK285459B6 SK1547-2001A SK15472001A SK285459B6 SK 285459 B6 SK285459 B6 SK 285459B6 SK 15472001 A SK15472001 A SK 15472001A SK 285459 B6 SK285459 B6 SK 285459B6
Authority
SK
Slovakia
Prior art keywords
saredutant
pharmaceutically acceptable
acceptable salts
treatment
prevention
Prior art date
Application number
SK1547-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK15472001A3 (sk
Inventor
Xavier Emonds-Alt
Philippe Soubrie
R�Gis Steinberg
Original Assignee
Sanofi - Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis
Publication of SK15472001A3 publication Critical patent/SK15472001A3/sk
Publication of SK285459B6 publication Critical patent/SK285459B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SK1547-2001A 1999-04-27 2000-04-25 Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu medicinálnych produktov, ktoré sú použiteľné na liečenie alebo prevenciu závažných depresívnych porúch SK285459B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
PCT/FR2000/001084 WO2000064423A2 (fr) 1999-04-27 2000-04-25 Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression

Publications (2)

Publication Number Publication Date
SK15472001A3 SK15472001A3 (sk) 2002-03-05
SK285459B6 true SK285459B6 (sk) 2007-02-01

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1547-2001A SK285459B6 (sk) 1999-04-27 2000-04-25 Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu medicinálnych produktov, ktoré sú použiteľné na liečenie alebo prevenciu závažných depresívnych porúch

Country Status (33)

Country Link
US (3) US6573281B1 (da)
EP (1) EP1173179B1 (da)
JP (1) JP2002542281A (da)
KR (1) KR20020001850A (da)
CN (1) CN1172669C (da)
AR (1) AR023597A1 (da)
AT (1) ATE234617T1 (da)
AU (1) AU764304B2 (da)
BG (1) BG65472B1 (da)
BR (1) BR0010006A (da)
CA (1) CA2370834C (da)
CZ (1) CZ294904B6 (da)
DE (1) DE60001725T2 (da)
DK (1) DK1173179T3 (da)
EE (1) EE05211B1 (da)
ES (1) ES2193065T3 (da)
FR (1) FR2792835B3 (da)
HK (1) HK1041821A1 (da)
HU (1) HUP0200969A3 (da)
IL (1) IL145269A0 (da)
MX (1) MXPA01010904A (da)
NO (1) NO20015228L (da)
NZ (1) NZ513851A (da)
PL (1) PL196479B1 (da)
PT (1) PT1173179E (da)
RU (1) RU2238726C2 (da)
SI (1) SI1173179T1 (da)
SK (1) SK285459B6 (da)
TR (1) TR200102512T2 (da)
TW (1) TWI225399B (da)
UA (1) UA69441C2 (da)
WO (1) WO2000064423A2 (da)
ZA (1) ZA200107143B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
ATE400563T1 (de) * 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE60114597T2 (de) * 2000-04-06 2006-07-20 Astrazeneca Ab Naphthamid-neurokinin antagonisten zur verwendung als medikamente
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
GB0019008D0 (en) 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) * 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
ATE549316T1 (de) * 2007-09-14 2012-03-15 Hoffmann La Roche Piperidinderivate als nk3-rezeptorantagonisten
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Also Published As

Publication number Publication date
EE200100553A (et) 2003-02-17
CZ20013812A3 (cs) 2002-02-13
US20030176462A1 (en) 2003-09-18
US6573281B1 (en) 2003-06-03
FR2792835B3 (fr) 2001-05-25
IL145269A0 (en) 2002-06-30
DK1173179T3 (da) 2003-07-14
UA69441C2 (uk) 2004-09-15
DE60001725T2 (de) 2004-02-05
CZ294904B6 (cs) 2005-04-13
HK1041821A1 (en) 2002-07-26
JP2002542281A (ja) 2002-12-10
FR2792835A1 (fr) 2000-11-03
NO20015228L (no) 2001-12-21
EP1173179B1 (fr) 2003-03-19
CA2370834C (en) 2007-09-25
TR200102512T2 (tr) 2002-04-22
TWI225399B (en) 2004-12-21
CN1348371A (zh) 2002-05-08
PL196479B1 (pl) 2008-01-31
ZA200107143B (en) 2002-10-30
AU4303400A (en) 2000-11-10
AU764304B2 (en) 2003-08-14
CN1172669C (zh) 2004-10-27
EE05211B1 (et) 2009-10-15
MXPA01010904A (es) 2002-06-21
BR0010006A (pt) 2002-01-15
ES2193065T3 (es) 2003-11-01
HUP0200969A2 (hu) 2002-07-29
EP1173179A2 (fr) 2002-01-23
NO20015228D0 (no) 2001-10-25
HUP0200969A3 (en) 2004-03-01
PL351922A1 (en) 2003-06-30
CA2370834A1 (en) 2000-11-02
DE60001725D1 (de) 2003-04-24
SK15472001A3 (sk) 2002-03-05
SI1173179T1 (en) 2003-06-30
NZ513851A (en) 2003-04-29
BG105962A (en) 2002-05-31
ATE234617T1 (de) 2003-04-15
WO2000064423A2 (fr) 2000-11-02
RU2238726C2 (ru) 2004-10-27
US7390823B2 (en) 2008-06-24
KR20020001850A (ko) 2002-01-09
PT1173179E (pt) 2003-06-30
BG65472B1 (bg) 2008-09-30
AR023597A1 (es) 2002-09-04
WO2000064423A3 (fr) 2001-04-19
US20080227818A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
US20080227818A1 (en) Use of saredutant or its pharmaceutically acceptable salts in the treatment of mixed anxiety-depression disorders
US6306904B1 (en) Antihistaminic/antitussive compositions
US20100021542A1 (en) Extended release oral dosage composition
PL201685B1 (pl) Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków
JPH07196499A (ja) 更年期症候群の治療法
JPH0313232B2 (da)
CZ152094A3 (en) Pharmaceutical preparation for reducing concentration of glucose in blood
JPH07215855A (ja) 自己免疫疾患を抑制する方法
JPH07215867A (ja) 卵巣発育不全、思春期遅滞または性的幼稚症を抑制する方法
JPH05509293A (ja) 不整脈および発作の治療における５―ｈｔ４受容体拮抗剤の使用
JPH1192369A (ja) 医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用
US6420388B1 (en) Osanetant in the treatment of depression and depressive disorders
JPH0377824A (ja) トリフルオロメチルフェニルテトラヒドロピリジン誘導体を含む腸管運動障害の予防用および／または治療用医薬製剤
US6586469B2 (en) Antihistaminic/antitussive compositions
JP3141051B2 (ja) 抗動脈硬化剤
HU197205B (en) Process for production of medical compositions against angine
SK19192000A3 (sk) Použitie paroxetínu alebo jeho farmaceuticky prijateľnej soli alebo solvátu na podporu odvykania od fajčenia alebo na zníženie alebo prevenciu relapsu fajčenia
US4105796A (en) Pharmaceutical compositions containing racemic or optically active 1-(2,6-dimethyl-phenoxy)-2-methylamino-propane and method of use
US20020058063A1 (en) Stable pharmaceutical dosage form for paroxetin anhydrate
US4021576A (en) Pharmaceutical compositions containing a 1-(2'-ethynyl-phenoxy)-2-hydroxy-3-(cycloalkyl-amino)-propane and method of use
HU213101B (en) Process for producing pharmaceutical composition of synergetic gastrocitoprotective activity, containing ranitidine and derivative of the salicylic acid
EP0048043A1 (en) Phenyl piperazine derivatives having analgetic activity
WO1996031238A1 (fr) Agent pour organes circulatoires
SK15672000A3 (sk) Použitie paroxetínu na liečenie generalizovaných anxióznych stavov

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120425